Inactief instrument

Andere talen Ibere Pharmaceuticals

Aandelen

Ibere Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14-11-22
Ibere Pharmaceuticals Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12-08-22
Ibere Pharmaceuticals Reports Earnings Results for the First Quarter Ended March 31, 2022	16-05-22
Ibere Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2021	31-03-22
Ibere Pharmaceuticals Auditor Raises 'Going Concern' Doubt	31-03-22
Ibere Pharmaceuticals Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12-11-21
Certain Class B Ordinary Shares of Ibere Pharmaceuticals are subject to a Lock-Up Agreement Ending on 24-AUG-2021.	24-08-21
Ibere Pharmaceuticals Reports Earnings Results for the Second Quarter Ended June 30, 2021	16-08-21
Ibere Pharmaceuticals : Letter dated August 4, 2021 from Marcum LLP (Form 8-K)	04-08-21
Ibere Pharmaceuticals : Receives Expected NYSE Notice Regarding Delayed Quarterly Report	29-05-21
Ibere Pharmaceuticals : Receives Expected NYSE Notice Regarding Delayed Quarterly Report (Form 8-K)	28-05-21
Ibere Pharmaceuticals announced that it has received $4.835 million in funding	02-03-21
Ibere Pharmaceuticals has completed an IPO in the amount of $120 million.	26-02-21
Ibere Pharmaceuticals announced that it expects to receive $4.835 million in funding	25-02-21
Ibere Pharmaceuticals has filed an IPO in the amount of $100 million.	08-02-21

Geen resultaten voor deze zoekopdracht